CD274 and neoplasm: Checkpoint-modulating agents targeting programmed death receptor-1 (PD-1) and its associated ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have been used as monotherapy or combination therapy monoclonal antibodies, showing long-term tumor containment and prolongation of survival (5).